Next Article in Journal
A Functional Analysis of the Unclassified Pro2767Ser BRCA2 Variant Reveals Its Potential Pathogenicity that Acts by Hampering DNA Binding and Homology-Mediated DNA Repair
Previous Article in Journal
A Network Analysis of Multiple Myeloma Related Gene Signatures
Open AccessArticle

Diclofenac Potentiates Sorafenib-Based Treatments of Hepatocellular Carcinoma by Enhancing Oxidative Stress

Department of Visceral Surgery, Lausanne University Hospital and University of Lausanne, Av de Beaumont, 1011 Lausanne, Switzerland
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(10), 1453; https://doi.org/10.3390/cancers11101453
Received: 23 August 2019 / Revised: 24 September 2019 / Accepted: 25 September 2019 / Published: 27 September 2019
Sorafenib is the first developed systemic treatment for advanced forms of hepatocellular carcinoma, which constitutes the most frequent form of primary liver cancers and is a major global health burden. Although statistically significant, the positive effect of sorafenib on median survival remains modest, highlighting the need to develop novel therapeutic approaches. In this report, we introduce diclofenac, a nonsteroidal anti-inflammatory drug, as a potent catalyzer of sorafenib anticancer efficacy. Treatment of three different hepatocellular cancer cells (Huh-7, HepG2, and PLC-PRF-5) with sorafenib (5 µM, 24 h) and diclofenac (100 µM, 24 h) significantly increased cancer cell death compared to sorafenib or diclofenac alone. Anti-oxidant compounds, including N-acetyl-cysteine and ascorbic acid, reversed the deleterious effects of diclofenac/sorafenib co-therapy, suggesting that the generation of toxic levels of oxidative stress was responsible for cell death. Accordingly, whereas diclofenac increased production of mitochondrial oxygen reactive species, sorafenib decreased concentrations of glutathione. We further show that tumor burden was significantly diminished in mice bearing tumor xenografts following sorafenib/diclofenac co-therapy when compared to sorafenib or diclofenac alone. Taken together, these results highlight the anticancer benefits of sorafenib/diclofenac co-therapy in hepatocellular carcinoma. They further indicate that combining sorafenib with compounds that increase oxidative stress represents a valuable treatment strategy in hepatocellular carcinoma. View Full-Text
Keywords: sorafenib; hepatocellular carcinoma; diclofenac; oxidative stress; cell death; co-therapy sorafenib; hepatocellular carcinoma; diclofenac; oxidative stress; cell death; co-therapy
Show Figures

Figure 1

MDPI and ACS Style

Duval, A.P.; Troquier, L.; de Souza Silva, O.; Demartines, N.; Dormond, O. Diclofenac Potentiates Sorafenib-Based Treatments of Hepatocellular Carcinoma by Enhancing Oxidative Stress. Cancers 2019, 11, 1453.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop